Lombard Odier Asset Management (Switzerland) SA - HALOZYME THERAPEUTICS INC ownership

HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 316 filers reported holding HALOZYME THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 0.23 and the average weighting 0.2%.

Quarter-by-quarter ownership
Lombard Odier Asset Management (Switzerland) SA ownership history of HALOZYME THERAPEUTICS INC
ValueSharesWeighting
Q1 2023$2,837,670
-84.1%
74,304
-76.3%
0.25%
-82.6%
Q4 2022$17,869,331
+13.9%
314,048
-20.8%
1.43%
+7.4%
Q3 2022$15,682,000
-15.4%
396,617
-5.9%
1.33%
-15.2%
Q2 2022$18,542,000
-24.3%
421,403
-31.4%
1.57%
-18.3%
Q1 2022$24,490,000
+79.8%
614,090
+104.7%
1.92%
+178.0%
Q2 2021$13,623,000
-27.4%
300,000
-33.3%
0.69%
-44.5%
Q1 2021$18,761,000
-6.5%
450,000
-4.3%
1.24%
-45.0%
Q4 2020$20,074,000
+38.9%
470,000
-14.5%
2.26%
+48.9%
Q3 2020$14,454,000
-14.4%
550,000
-12.7%
1.52%
-41.9%
Q2 2020$16,890,000
+4.3%
630,000
-30.0%
2.61%
+20.5%
Q1 2020$16,191,000
+1.5%
900,0000.0%2.17%
+44.7%
Q4 2019$15,957,000
+242.9%
900,000
+200.0%
1.50%
+198.6%
Q3 2019$4,653,000
-50.8%
300,000
-45.5%
0.50%
-47.7%
Q2 2019$9,449,000
+4.0%
550,000
+10.0%
0.96%
+6.5%
Q3 2018$9,085,000
+38.2%
500,000
+54.1%
0.90%
+41.2%
Q4 2017$6,574,000
+89.2%
324,500
+62.2%
0.64%
+89.3%
Q3 2017$3,474,000
+95.3%
200,000
+44.1%
0.34%
+65.2%
Q2 2017$1,779,000
-54.2%
138,775
-53.7%
0.20%
-52.7%
Q1 2017$3,888,000
+9.3%
300,000
-16.7%
0.43%
-52.0%
Q4 2016$3,557,000
+49.0%
360,000
+80.0%
0.90%
+57.5%
Q3 2016$2,388,000
-71.3%
200,000
-58.3%
0.57%
-43.2%
Q4 2015$8,318,000
+69.0%
480,000
+120.2%
1.00%
+171.8%
Q2 2015$4,922,000
+16.9%
218,000
-48.9%
0.37%
-20.8%
Q2 2014$4,210,000426,3000.47%
Other shareholders
HALOZYME THERAPEUTICS INC shareholders Q1 2022
NameSharesValueWeighting ↓
Third Security, LLC 19,829,337$266,308,00010.60%
BB BIOTECH AG 6,929,832$93,068,0002.95%
SECTORAL ASSET MANAGEMENT INC 2,671,051$35,872,0001.64%
Sterling Global Strategies LLC 22,000$295,0001.63%
Lombard Odier Asset Management (USA) Corp 1,061,547$14,257,0001.24%
PYRRHO CAPITAL MANAGEMENT, LP 90,000$1,209,0001.04%
IRIDIAN ASSET MANAGEMENT LLC/CT 8,184,003$109,911,0000.93%
Bellevue Asset Management AG 246,000$3,304,0000.54%
Convergence Investment Partners, LLC 251,748$3,381,0000.39%
Rhenman & Partners Asset Management AB 172,000$2,310,0000.37%
View complete list of HALOZYME THERAPEUTICS INC shareholders